IL151791A0 - Pharmaceutical composition for the treatment of respiratory diseases - Google Patents

Pharmaceutical composition for the treatment of respiratory diseases

Info

Publication number
IL151791A0
IL151791A0 IL15179101A IL15179101A IL151791A0 IL 151791 A0 IL151791 A0 IL 151791A0 IL 15179101 A IL15179101 A IL 15179101A IL 15179101 A IL15179101 A IL 15179101A IL 151791 A0 IL151791 A0 IL 151791A0
Authority
IL
Israel
Prior art keywords
treatment
pharmaceutical composition
respiratory diseases
glycopyrrolate
dry powder
Prior art date
Application number
IL15179101A
Other languages
English (en)
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL151791(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arakis Ltd filed Critical Arakis Ltd
Publication of IL151791A0 publication Critical patent/IL151791A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
IL15179101A 2000-04-07 2001-04-09 Pharmaceutical composition for the treatment of respiratory diseases IL151791A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (en) 2000-04-07 2001-04-09 The treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
IL151791A0 true IL151791A0 (en) 2003-04-10

Family

ID=9889490

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15179101A IL151791A0 (en) 2000-04-07 2001-04-09 Pharmaceutical composition for the treatment of respiratory diseases
IL151791A IL151791A (en) 2000-04-07 2002-09-18 Use of a dry powder containing glycopyrulate micro-particles for the preparation of a pharmaceutical preparation for the treatment of respiratory diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151791A IL151791A (en) 2000-04-07 2002-09-18 Use of a dry powder containing glycopyrulate micro-particles for the preparation of a pharmaceutical preparation for the treatment of respiratory diseases

Country Status (25)

Country Link
US (3) US7229607B2 (enExample)
EP (3) EP1449528B1 (enExample)
JP (1) JP5042426B2 (enExample)
CN (3) CN1720995A (enExample)
AT (1) ATE330585T2 (enExample)
AU (2) AU2004242450B2 (enExample)
BE (1) BE2013C023I2 (enExample)
BR (1) BR0109875A (enExample)
CA (1) CA2405705C (enExample)
CY (1) CY1105120T1 (enExample)
DE (1) DE60120936T3 (enExample)
DK (1) DK1267866T4 (enExample)
ES (2) ES2266242T5 (enExample)
GB (1) GB0008660D0 (enExample)
HK (1) HK1050846B (enExample)
HU (2) HU230958B1 (enExample)
IL (2) IL151791A0 (enExample)
LU (2) LU92166I2 (enExample)
MX (1) MXPA02009718A (enExample)
NO (3) NO336142B1 (enExample)
NZ (2) NZ521476A (enExample)
PL (1) PL364024A1 (enExample)
PT (1) PT1267866E (enExample)
WO (1) WO2001076575A2 (enExample)
ZA (1) ZA200207420B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EP1337239B2 (en) 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
EP2298285A3 (en) 2000-11-30 2011-07-27 Vectura Limited Method of making particles for use in a pharmaceutical composition
CA2341952A1 (en) 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
MXPA03010672A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Composicion para el tratamiento regenerativo de enfermedades del cartilago.
PT3494995T (pt) * 2002-03-01 2020-03-30 Chiesi Farm Spa Formulação superfina de formoterol
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) * 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2005014825A2 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005048985A2 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
ES2309705T3 (es) * 2004-02-06 2008-12-16 MEDA PHARMA GMBH & CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
SI1713473T1 (sl) 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
JP2007520509A (ja) * 2004-02-06 2007-07-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト 抗コリン薬による、又は抗ヒスタミン薬、ホスホジエステラーゼ４、又はコルチコステロイドとの組み合わせによる鼻炎治療薬
WO2005082413A2 (en) * 2004-02-27 2005-09-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
JP2007528409A (ja) * 2004-03-09 2007-10-11 アリバ ファーマシューティカルズ， インコーポレイテッド プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1763344A1 (en) * 2004-06-29 2007-03-21 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising steroids and an anticholinergic
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
EP1789018A1 (en) 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
CA2595791C (en) 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
JP2008534480A (ja) * 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用
WO2007070843A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
PL2098248T3 (pl) * 2005-12-21 2012-11-30 Meda Pharma Gmbh & Co Kg Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
KR20100099281A (ko) * 2007-12-13 2010-09-10 노파르티스 아게 유기 화합물
BRPI0820745A2 (pt) * 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2435025B1 (en) * 2009-05-29 2016-07-06 Pearl Therapeutics, Inc. Respiratory delivery of active agents
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
CN102665678B (zh) 2009-12-23 2014-07-02 奇斯药制品公司 用于copd的联合治疗
JP5914354B2 (ja) 2009-12-23 2016-05-11 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Ｃｏｐｄ用併用療法
CN102695496B (zh) 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
GEP20166479B (en) 2009-12-23 2016-05-25 Chiesi Farma Spa Aerosol formulation for copd
CA3086367A1 (en) * 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
LT2739268T (lt) 2011-08-01 2019-03-25 Monash University Inhaliacijos būdas ir kompozicija
EP2819672A1 (en) 2012-02-29 2015-01-07 Pulmatrix, Inc. Inhalable dry powders
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
US20160317391A1 (en) * 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
HRP20181551T1 (hr) 2013-12-30 2018-11-30 Chiesi Farmaceutici S.P.A. Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
PL3191081T3 (pl) 2014-09-09 2020-09-07 Vectura Limited Formulacja zawierająca glikopirolan, sposób i urządzenie
HUE055527T2 (hu) * 2014-09-15 2021-12-28 Verona Pharma Plc RPL554-t tartalmazó folyékony inhalációs készítmény
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
ES2942176T3 (es) * 2015-06-15 2023-05-30 Qaam Pharmaceuticals Llc Sales de ácidos grasos de glicopirronio y métodos para su elaboración
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
MX2022004781A (es) 2019-12-02 2022-05-16 Chiesi Farm Spa Lata de acero inoxidable para inhaladores dosificadores presurizados.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SA95160463B1 (ar) * 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
ATE238280T1 (de) 1996-11-11 2003-05-15 Christian R Noe Verwendung eines pharmazeutisch geeigneten salzes von (3r,2'r)-3-((cyclopentyl- hydroxyphenylacetyl)oxy)-1,1-dimethyl- pyrrolidinium zur herstellung eines arzneimittels
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ATE287257T1 (de) * 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
DK1014943T3 (da) * 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6585958B1 (en) * 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
WO2000007567A1 (de) * 1998-08-04 2000-02-17 Jago Research Ag Medizinische aerosolformulierungen
DK1131059T3 (da) 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU7389300A (en) * 1999-08-02 2001-02-19 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) * 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 漢高智慧財產控股公司 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
HUS1900056I1 (hu) 2020-02-28
GB0008660D0 (en) 2000-05-31
LU92393I2 (fr) 2015-11-02
JP5042426B2 (ja) 2012-10-03
ES2266242T5 (es) 2016-10-04
CN1720995A (zh) 2006-01-18
CA2405705A1 (en) 2001-10-18
HU230958B1 (hu) 2019-06-28
PL364024A1 (en) 2004-11-29
NO20024708L (no) 2002-10-24
EP1267866A2 (en) 2003-01-02
AU2004242450B2 (en) 2010-06-03
IL151791A (en) 2015-05-31
CA2405705C (en) 2011-06-07
CN101181263A (zh) 2008-05-21
HK1050846A1 (en) 2003-07-11
EP1267866B1 (en) 2006-06-21
JP2003530344A (ja) 2003-10-14
EP1449528B1 (en) 2018-08-08
US8029768B2 (en) 2011-10-04
PT1267866E (pt) 2006-10-31
EP1449528A1 (en) 2004-08-25
EP1267866B2 (en) 2016-07-20
US20050019271A1 (en) 2005-01-27
ES2266242T3 (es) 2007-03-01
NO2015025I1 (no) 2015-12-07
WO2001076575A3 (en) 2002-03-28
US7368104B2 (en) 2008-05-06
CN1292745C (zh) 2007-01-03
AU2010200660B2 (en) 2012-04-19
AU2004242450A1 (en) 2005-01-20
DE60120936T3 (de) 2016-11-17
NO2015024I1 (no) 2015-11-25
BE2013C023I2 (enExample) 2020-06-24
MXPA02009718A (es) 2003-05-27
NO2015024I2 (no) 2015-11-25
AU2010200660A1 (en) 2010-03-11
HK1050846B (en) 2007-01-26
AU776913B2 (en) 2004-09-23
CY1105120T1 (el) 2010-03-03
US20030068280A1 (en) 2003-04-10
LU92166I2 (fr) 2014-03-13
NZ521476A (en) 2004-10-29
BR0109875A (pt) 2004-07-20
CN1422154A (zh) 2003-06-04
ES2687751T3 (es) 2018-10-29
DK1267866T3 (da) 2006-10-23
WO2001076575A2 (en) 2001-10-18
US20080220073A1 (en) 2008-09-11
DK1267866T4 (en) 2016-10-03
US7229607B2 (en) 2007-06-12
NO336142B1 (no) 2015-05-26
ATE330585T2 (de) 2006-07-15
EP2193791A1 (en) 2010-06-09
CN101181263B (zh) 2011-07-06
AU8930601A (en) 2001-10-23
NO20024708D0 (no) 2002-10-01
DE60120936D1 (de) 2006-08-03
DE60120936T2 (de) 2006-11-02
ZA200207420B (en) 2003-09-16
HUP0301518A2 (hu) 2003-08-28
NZ535284A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
HUS1900056I1 (hu) Légzési rendellenességek kezelésére alkalmas, glikopirrolát tartalmú száraz porkészítményt tartalmazó inhaláló készülék és alkalmazása
MXPA02011311A (es) Composicion novedosa.
IL167900A (en) Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
YU36302A (sh) Novi tiotropiumski preparati - koji sadrže prah za inhaliranje
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DE60318193D1 (en) Phenethanolaminderivate
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
WO2004037807A3 (en) Medicinal arylethanolamine compounds
IL152532A0 (en) Pharmaceutical compositions comprising micronised formoterol and process for their preparation
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
MY148125A (en) Compounds
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
MY145166A (en) Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
MXPA04007294A (es) Composicion para inhalacion.
EP1390012A4 (en) NEW METHODS AND COMPOSITIONS FOR RELEASING MACROMOLECULES TO OR BY THE AIRWAY
WO2005011615A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
IL165574A0 (en) Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
SG163512A1 (en) Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion

Legal Events

Date Code Title Description
EXTE Period for filing application for extension order has been extended (section 64p.(4))